Dr Tony Dhillon


Medical oncology

  • is fee assuredFee assured

This healthcare professional is currently treating patients. Please speak to them to find out more about their availability.

Last updated: 12 Nov 2020

Specialises in

  • Colon
  • Hepatobiliary
  • Lower GI


  • Home chemotherapy

About me

I am Consultant Medical Oncologist at the Royal Surrey County Hospital in Guildford and Senior Lecturer in Oncology at the University of Surrey. I specialise in colorectal, pancreatic, liver and gallbladder/bile duct cancers.

I gained a Bachelor of science in 1994, qualified in Medicine from University College London in 1997 and obtained my PhD on cancer cell signalling from Imperial College London in 2009, funded by a Cancer Research-UK (CR-UK) clinical training fellowship.

I have previously been a Welcome Trust clinical fellow in the University of Oxford and Senior Lecturer in Oncology at Imperial College London.

I have an active research programme: I am chief investigator for two major Immunotherapy trials in colorectal cancer- High POLE and POLEM. I also have a special interest in Liver cancer research.

I am a member of the National Cancer Research Institute (NCRI) Colorectal Adjuvant & Advanced Disease Sub-Group and National Institute of Health Research (NIHR) Kent, Surrey and Sussex Clinical Research Network sub-speciality lead for colorectal cancer research.

Research and Interests

I am Senior Lecturer in Oncology at the University of Surrey.

My main research interests are in potential new treatments in bowel, liver and pancreatic cancer. I have a particular interest in immuno-oncology.

In bowel cancer, I am interested in sub-types which maybe more sensitive to checkpoint inhibitor drugs. These groups include microsatellite instability- high patients (MSI-High) caused by the loss of DNA mismatch repair activity and mutations in the DNA and pathogenic variants in two proofreading DNA repair genes POLD1 and POLE. Both these groups have an ultramutated phenotype.

I have got funding from 2 drug companies for clinical trials in these groups of patients of checkpoint inhibitor drugs including common immunology translational endpoints.

We are hoping that these trials will lead to an improvement in survival in these patients. These trials are considered to be the most important in the UK.

Areas of interest

Colon; Hepato-biliary; Lower GI; GIST; NET. Chemotherapy, immunotherapy and targeted treatments. Research and clinical trials

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

Report this page Edit details

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.